AU2006279400A1 - Combination methods of SAHA and Targretin for treating cancer - Google Patents

Combination methods of SAHA and Targretin for treating cancer Download PDF

Info

Publication number
AU2006279400A1
AU2006279400A1 AU2006279400A AU2006279400A AU2006279400A1 AU 2006279400 A1 AU2006279400 A1 AU 2006279400A1 AU 2006279400 A AU2006279400 A AU 2006279400A AU 2006279400 A AU2006279400 A AU 2006279400A AU 2006279400 A1 AU2006279400 A1 AU 2006279400A1
Authority
AU
Australia
Prior art keywords
administered
day
saha
dose
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006279400A
Other languages
English (en)
Inventor
Steven Averbuch
Stanley R. Frankel
Victoria M. Richon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2006279400A1 publication Critical patent/AU2006279400A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006279400A 2005-08-18 2006-08-18 Combination methods of SAHA and Targretin for treating cancer Abandoned AU2006279400A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70959905P 2005-08-18 2005-08-18
US60/709,599 2005-08-18
US73375205P 2005-11-04 2005-11-04
US60/733,752 2005-11-04
PCT/US2006/032282 WO2007022408A2 (en) 2005-08-18 2006-08-18 Combination methods of saha and targretin for treating cancer

Publications (1)

Publication Number Publication Date
AU2006279400A1 true AU2006279400A1 (en) 2007-02-22

Family

ID=37758430

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006279400A Abandoned AU2006279400A1 (en) 2005-08-18 2006-08-18 Combination methods of SAHA and Targretin for treating cancer

Country Status (6)

Country Link
US (1) US20090227674A1 (enExample)
EP (1) EP1933825A2 (enExample)
JP (1) JP2009504774A (enExample)
AU (1) AU2006279400A1 (enExample)
CA (1) CA2617623A1 (enExample)
WO (1) WO2007022408A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322160A1 (en) * 2002-03-04 2011-05-18 Merck HDAC Research, LLC Methods of inducing terminal differentiation
TWI415603B (zh) 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
DK1937244T3 (en) 2005-09-30 2018-10-29 Io Therapeutics Llc : CANCER TREATMENT WITH SPECIFIC RXR AGONISTS
WO2008132443A1 (en) * 2007-04-25 2008-11-06 Cyclacel Limited Use of sapacitabine to treat proliferative disease
CN104114171A (zh) 2011-12-13 2014-10-22 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
CN105939716A (zh) * 2013-12-03 2016-09-14 埃斯泰隆制药公司 组蛋白脱乙酰基酶抑制剂和免疫调节药物的组合
AU2015262349A1 (en) * 2014-05-21 2017-02-02 National Institute Of Advanced Industrial Science And Technology Cancer stem cell proliferation inhibitor
WO2016164770A1 (en) * 2015-04-10 2016-10-13 Bioresponse, L.L.C. Self-emulsifying formulations of dim-related indoles
MX364892B (es) * 2015-10-31 2019-05-10 Io Therapeutics Inc Tratamiento de trastornos del sistema nervioso utilizando combinaciones de agonistas de rxr y hormonas tiroideas.
EP3426302B1 (en) 2016-03-10 2022-12-14 IO Therapeutics, Inc. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
DK3426303T3 (da) * 2016-03-10 2022-09-19 Io Therapeutics Inc Behandling af muskellidelser med kombinationer af rxr-agonister og thyroideahormoner
WO2018089861A1 (en) * 2016-11-11 2018-05-17 The Regents Of The University Of California Methods and compositions for the treatment of cancer and metabolic diseases
EP3684348A4 (en) 2017-09-20 2021-08-18 IO Therapeutics, Inc. TREATMENT OF DISEASE WITH SELECTIVE RXR AGONIST ESTERS
WO2020232399A1 (en) * 2019-05-16 2020-11-19 The Regents Of The University Of California Compositions comprising hdac inhibitors and retinoids
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
JP2024543621A (ja) 2021-12-07 2024-11-21 アイオー セラピューティクス インコーポレイテッド Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストおよびタキサンの使用
WO2023108015A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors

Also Published As

Publication number Publication date
US20090227674A1 (en) 2009-09-10
WO2007022408A3 (en) 2007-09-27
JP2009504774A (ja) 2009-02-05
EP1933825A2 (en) 2008-06-25
CA2617623A1 (en) 2007-02-22
WO2007022408A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
US20070197568A1 (en) Methods of using SAHA and Erlotinib for treating cancer
US20070197473A1 (en) Methods of using SAHA and Bortezomib for treating cancer
CN1964714B (zh) 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
US20090227674A1 (en) Combination methods fo saha and targretin for treating cancer
US20120142770A1 (en) Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
US20100113392A1 (en) Methods of using saha and bortezomib for treating multiple myeloma
AU2006311829B8 (en) Methods of treating cancers with SAHA, Carboplatin, and Paclitaxel and other combination therapies
WO2007056243A2 (en) Methods of treating cancers with saha and fluorouracil and other combination therapies
HK1124783A (en) Methods of using saha and erlotinib for treating cancer

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period